Synovitis in the first carpometacarpal joint at the base of the thumb predicts structural hand osteoarthritis progression just as strongly as inflammation in the interphalangeal joints, according to a prospective cohort study published in RMD Open. Led by Marthe Gløersen, MD, of Diakonhjemmet Hospital in Oslo, Norway, the research establishes that clinicians can rely on baseline joint inflammation in either location to forecast radiographic worsening over an average follow-up of 3.4 years.
Synovitis Risk Profile in Hand Osteoarthritis Subtypes
Hand osteoarthritis has traditionally been divided into distinct clinical subtypes, separating first carpometacarpal (CMC1) joint involvement from disease affecting the interphalangeal joints. While joint inflammation, or synovitis, is widely recognized as a primary driver of structural deterioration, researchers questioned whether prognostic significance remained consistent across these different anatomical locations. To investigate this, Gløersen and colleagues utilized data from the Nor-Hand study, tracking 201 patients evaluated between 2016 and 2017 with follow-up visits spanning 2019 to 2021.
The analysis revealed that patients exhibiting high-grade synovitis in the CMC1 joint at baseline faced 9.3-fold greater odds of clinically relevant radiographic progression, with a 95% confidence interval ranging from 2.2 to 39.6. By comparison, baseline synovitis in predominantly interphalangeal osteoarthritis yielded an odds ratio of 23.4, with a 95% confidence interval spanning 10.4 to 52.9. Because these confidence intervals broadly overlap, researchers determined the prognostic impact is comparable across both joint groups.
| Joint Location | Synovitis Severity | Odds Ratio (Radiographic Progression) |
|---|---|---|
| CMC1 Joint (Thumb Base) | Grade 3 Synovitis | 9.3 (95% CI 2.2–39.6) |
| Interphalangeal Joints | Grade 3 Synovitis | 23.4 (95% CI 10.4–52.9) |
| Either Joint Type | Grade 1 Synovitis | 2.2–2.8 |
Imaging Methods and Patient Cohort Details
The Diakonhjemmet Hospital cohort comprised patients with a mean age of 61, nearly 90% of whom were women. Across the 201 participants, researchers assessed 397 CMC1 joints and 3,608 interphalangeal joints using ultrasound and MRI scans at baseline. Structural status was quantified using standard x-rays scored on the Kellgren-Lawrence scale of 0 to 3, tracking joint space narrowing and erosions. Baseline distribution showed that 12% of patients had osteoarthritis restricted to the CMC1 joint, 47% had disease exclusive to the interphalangeal joints, and the remainder exhibited involvement in both areas.
Any degree of grey-scale synovitis at baseline accurately forecast radiographic progression, with predictive strength increasing alongside inflammation severity. Grade 1 synovitis produced odds ratios between 2.2 and 2.8 compared to joints free of inflammation. Baseline osteophytes and joint space narrowing followed a similar trajectory, though associations for joint space narrowing reached statistical significance exclusively in interphalangeal joints. Power Doppler ultrasound assessments also pointed toward future progression, though fewer patients exhibited high-grade vascularized inflammation using this modality, limiting statistical power.
Did you know?
While intra-articular corticosteroid injections often reduce movement-related pain in interphalangeal osteoarthritis, randomized trials specifically evaluating CMC1 osteoarthritis have found no significant pain benefit compared to saline or local anesthesia.
Therapeutic Implications and Study Limitations
The findings highlight a persistent clinical challenge: whether early intervention targeting synovitis can alter structural disease trajectories. According to the research team, the efficacy of intra-articular corticosteroid injections varies widely depending on the targeted joint group. Ongoing investigations, such as the PICASSO trial, are actively evaluating steroid treatments for pain relief in CMC1 joints, though structural preservation remains outside their primary scope. Effective disease-modifying therapies that prevent osteoarthritis progression outside of joint replacement surgery are not yet available.
Study authors noted several limitations affecting the analysis. The relatively small count of evaluated CMC1 joints reduced statistical power for specific secondary comparisons. Furthermore, because the work relied on a single-center cohort drawn from a high-income, predominantly white region, the findings may not generalize to routine clinical care populations in other healthcare settings.
Frequently Asked Questions
What is hand osteoarthritis synovitis?
Synovitis refers to inflammation located within the synovial membrane of a joint. In hand osteoarthritis, it serves as a major risk factor for future structural degradation and radiographic progression.
How does CMC1 osteoarthritis differ from interphalangeal osteoarthritis?
CMC1 osteoarthritis affects the base of the thumb at the carpometacarpal joint, whereas interphalangeal osteoarthritis impacts the more distal joints of the fingers and thumb. They have historically been evaluated as distinct clinical subtypes.
Do steroid injections stop structural progression in hand osteoarthritis?
Currently, no approved disease-modifying therapy stops structural progression outside of joint replacement. While corticosteroid injections can ease pain in certain joint groups, their structural benefits remain unproven.
Explore our latest clinical research updates and subscribe to our newsletter to receive weekly medical news directly in your inbox.
Related reading